Braveheart Bio (NASDAQ:BRVE) CFO James Paul Rickey Purchases 27,777 Shares

Posted by on Aug 8th, 2026

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) CFO James Paul Rickey bought 27,777 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $499,986.00. Following the purchase, the chief financial officer owned 520,927 shares of the company’s stock, valued at approximately $9,376,686. The trade was a 5.63% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Braveheart Bio Stock Up 0.7%

Shares of BRVE stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a 12 month low of $28.47 and a 12 month high of $32.00.

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

Read More

Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.